GTC Biotherapeutics (fka GTCB)

[Pre_Clinical]

<<<<<
>…some aglycosylated proteins (proteins that are normally glycosylated but manufactured in a non-glycosylated form) sometimes have a tendency to be more labile to proteolysis, aggregation, and immunogenicity.<

1. GTC’s drug candidates can turn out differently glycosylated from their endogenous counterparts, but they are not aglycosylated.

2. In several clinical trials dating to the 1990s, ATryn has shown no immunogenicity in a large pool of human recipients. You may be barking up the wrong tree here.
<<<<<<<<<<

Im not barking up wrong the tree, I never once said the Atryn was immunogenic.

I'm simply trying to evaluate the strengths and weakness of this technology platform as a potential breakthrough modality for the production of recombinant proteins. So far, from what I've gathered, the glycosylation pattern of the company's lead protein is significantly different from the glycosylation pattern of the plasma derived AT, which fortuitously for this protein is not important to its pharmacokinetic/pharmacodynamic profile, and in fact may be beneficial.

However, the question that I'm asking is how universal is this technology going to be? Is it going to be limited to serpin scaffolds like ATIII and antitrypsin? If so, that's fine, there's a nice niche there. Or is it going to be useful to Abs as well?

I am completely on board with the improved yields/COGS analysis of transgenic milk derived material.

The only question that I have is regarding the degree to which variability in the post-translational modifications of recombinant proteins expressed in transgenic milk will limit the impact of this technology.